Education
About Us
Working with TipRanks
Follow Us
Lynn Seely Insider Profile
4 Followers
Lynn Seely, CMO at Medivation, holds 17.16K shares in Blueprint Medicines (Ticker: BPMC), holds 712.50K shares in Lyell Immunopharma (Ticker: LYEL), holds 1.89M shares in Myovant Sciences (Ticker: MYOV).
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
-4.00%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Lynn Seely holds in companies
Most Profitable Insider Trade
The most profitable trade made by Lynn Seely
Lynn Seely's Trading History
Medivation
Feb 10, 2015
―
Uninformative Buy
―
$7.81M
Blueprint Medicines
Jun 24, 2025
Director
Uninformative Buy
499.92K
$2.22M
Myovant Sciences
Apr 07, 2020
―
Uninformative Buy
―
$50.99M
Lyell Immunopharma
Mar 18, 2025
President & CEO, Director
Informative Buy
105.00K
$6.58M
List of latest transactions for each holding click on a transaction to see Lynn Seely's performance on stock
You May Also Like
Lynn Seely insider profile FAQ
What is the percentage of profitable transactions made by Lynn Seely?
The percentage of profitable transactions made by Lynn Seely is 50%.
What is the average return per transaction made by Lynn Seely?
The average return per transaction made by Lynn Seely is -4.00%.
What stocks does Lynn Seely hold?
Lynn Seely holds: MDVN, BPMC, MYOV, LYEL stocks.
What was Lynn Seely’s latest transaction?
Lynn Seely latest transaction was an Uninformative Buy of $499.92K.
What was Lynn Seely's most profitable transaction?
Lynn Seely’s most profitable transaction was an Informative Buy of LYEL stock on March 18, 2025. The return on the trade was 0.70%.
What is Lynn Seely's role in Medivation?
Lynn Seely's role in Medivation is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.